B
Bender John A
Researcher at Bristol-Myers Squibb
Publications - 37
Citations - 916
Bender John A is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Hepatitis C virus & NS5B. The author has an hindex of 16, co-authored 37 publications receiving 870 citations. Previous affiliations of Bender John A include University of Texas at Austin.
Papers
More filters
Patent
Compounds for the treatment of hepatitis c
Kap-Sun Yeung,Kyle Parcella,Bender John A,Brett R. Beno,Katharine A. Grant-Young,Han Ying,Piyasena Hewawasam,John F. Kadow,Andrew Nickel +8 more
TL;DR: In this paper, the authors have proposed compounds of formula I as well as compositions and methods of using the compounds, which have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Journal ArticleDOI
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.
Tao Wang,Zhiwei Yin,Zhongxing Zhang,Bender John A,Zhong Yang,Graham Johnson,Zheng Yang,Lisa Zadjura,Celia D’Arienzo,Dawn D. Parker,Christophe Gesenberg,Gregory Yamanaka,Yi-Fei Gong,Hsu-Tso Ho,Hua Fang,Nannan Zhou,Brian McAuliffe,Betsy J. Eggers,Li Fan,Beata Nowicka-Sans,Ira B. Dicker,Qi Gao,Richard J. Colonno,Pin-Fang Lin,Nicholas A. Meanwell,John F. Kadow +25 more
TL;DR: 4 azaindole derivatives derived from the screening lead, administered as monotherapy for 8 days, reduced viremia in HIV-1-infected subjects, providing proof of concept for this mechanistic class.
Patent
Antiviral azaindole derivatives
TL;DR: The present invention is directed to a series of chemical entities that express HIV-1 inhibitory activities as discussed by the authors, and is based on the work of the authors of the present paper.
Patent
Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
TL;DR: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV as mentioned in this paper.
Journal ArticleDOI
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.
Robert G. Gentles,Min Ding,Bender John A,Bergstrom Carl P,Katharine A. Grant-Young,Piyasena Hewawasam,Thomas W. Hudyma,Scott W. Martin,Andrew Nickel,Alicia Regueiro-Ren,Yong Tu,Zhong Yang,Kap-Sun Yeung,Xiaofan Zheng,Sam T. Chao,Jung-Hui Sun,Brett R. Beno,Daniel M. Camac,Chong-Hwan Chang,Mian Gao,Paul E. Morin,Steven Sheriff,Jeff Tredup,John Wan,Mark R. Witmer,Dianlin Xie,Umesh Hanumegowda,Jay O. Knipe,Kathy Mosure,Kenneth S. Santone,Dawn D. Parker,Xiaoliang Zhuo,Julie A. Lemm,Mengping Liu,Lenore A. Pelosi,Karen Rigat,Voss Stacey A,Yi Wang,Ying-Kai Wang,Richard J. Colonno,Min Gao,Susan B. Roberts,Qi Gao,Alicia Ng,Nicholas A. Meanwell,John F. Kadow +45 more
TL;DR: Structural-activity relationship studies resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors, and analogues exhibiting improved solubility and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.